Showing 2381-2390 of 20409 results for "".
Sudden Cardiac Death Prevention: ICD Indications
https://reachmd.com/programs/clinicians-roundtable/sudden-cardiac-death-prevention-icd-indications/3681/Patients with advanced heart failure are at increased risk for sudden cardiac arrest, but many of them are not receiving ICD therapy. Dr. Jeanne Poole, professor of medicine and cardiology at the University of Washington, Seattle, will review with host Dr. Matthew Sorrentino the indications for ICDThe Rise in Diagnosis of ACL Injuries in Children
https://reachmd.com/programs/clinicians-roundtable/the-rise-in-diagnosis-of-acl-injuries-in-children/2995/In years past, we understood that children rarely suffered ACL injuries. But we're now learning that this diagnosis, previously reserved for adults, has become increasingly common in children. How can we best counsel a young patient who suffers an ACL injury? Host Dr. Mark Nolan Hill welcomes Dr. MiIdentifying Unmet Needs in the Management of Glomerular Diseases
https://reachmd.com/programs/clinicians-roundtable/identifying-unmet-needs-in-the-management-of-glomerular-diseases/14906/Are you facing challenges when managing patients with glomerular diseases like IgA nephropathy and C3 glomerulopathy? If so, you’re not alone.Do Celebrity Heart Attacks Influence Public Health?
https://reachmd.com/programs/lipid-luminations/do-celebrity-heart-attacks-influence-public-health/3569/Celebrities, often criticized for their dubious influence on the public, may inadvertently promote good health when a famous celebrity dies from a heart attack. Dr. James Erhlich discusses how the sudden death of a famous person heightens the general population’s interest in cardiovascuManagement Issues in Familial Hypercholesterolemia
https://reachmd.com/programs/lipid-luminations/management-issues-in-familial-hypercholesterolemia/6480/Host Dr. Alan Brown discusses management issues and practical advice with certified registered nurse practitioner and clinical lipid specialist Joyce Ross, who says that familial hypercholesterolemia (FH) is the most common genetic disorder, and many who have it are totally unaware of their conditiHow to Use Medical Education as a Tool for Practice Quality Improvement
https://reachmd.com/programs/lifelong-learning/how-to-use-medical-education-as-a-tool-for-practice-quality-improvement/7159/"Quality improvement is not an event or a project; it's a continuous process." This is the sentiment of special guest Louis Diamond, President of the Quality in Health Care Advisory Group, LLC. Mr. Diamond also serves as Quality Improvement Education Initiation Chair for ACEHP. He joins host AliciaSupplement Use for Colorectal Cancer Prevention: Insights from NCCN Guidelines
https://reachmd.com/programs/clinicians-roundtable/supplement-use-for-colorectal-cancer-prevention-insights-from-nccn-guidelines/36406/According to the NCCN Guidelines for Colorectal Cancer Screening, there is mixed evidence around the impact of vitamin D, calcium, folate, and aspirin on colorectal cancer risk. Join Dr. Reid Ness as he discusses considerations for recommending these supplements based on patient-specific factors. DCollaboration in Medical Affairs: Increasing Value and Impact
https://reachmd.com/programs/maps-chats/collaboration-medical-affairs/56812/What do pharmaceutical leaders actually need from their agency partners? Find out as Dr. Matt Birnholz sits down with Dr. Renu Juneja to explore how insight-led collaboration can unlock stronger relationships, faster timelines, and more impactful medical education. In this conversation at the 2026 MDesigning Smarter Insight Frameworks in Medical Affairs
https://reachmd.com/programs/maps-chats/design-smart-insight-frameworks-medical-affairs/56813/Early, integrated insights can dramatically improve pharmaceutical launch outcomes and reduce the risk of missed expectations. Discover best practices for aligning market needs with clinical strategy and leveraging AI for smarter insight planning with Dr. Matt Birnholz and Mr. Tony Page, who sharedRNAi Therapeutics in ATTR-CM: Clinical Evidence and Potential Impacts
https://reachmd.com/programs/on-the-frontlines-of-attr-cm/rnai-attr-cm-evidence-impacts/49040/Emerging evidence supports the use of RNA interference (RNAi) therapeutics to treat transthyretin cardiac amyloidosis (ATTR-CM). Dr. Shelina Ramnarine sits down with Dr. Chadi Alraies to explore findings from a systematic review and meta-analysis highlighting improvements in survival, function